Novel drug targets imatinib-refractory leukemia: two studies suggest that nilotinib could provide an alternative for patients not benefiting from imatinib.(Hematology): ... An article from: Internal Medicine News
This digital document is an article from Internal Medicine News, published by Thomson Gale on January 15, 2007. The length of the article is 756 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.
Citation Details
Title: Novel drug targets imatinib-refractory leukemia: two studies suggest that nilotinib could provide an alternative for patients not benefiting from imatinib.(Hematology)
Author: Bruce Wilson
Publication: Internal Medicine News (Magazine/Journal)
Date: January 15, 2007
Publisher: Thomson Gale
Volume: 40 Issue: 2 Page: 24(1)
List Price: $ 9.95
Price: $ 9.95
Leukemia — Comprehensive overview covers symptoms, causes, risk factors, treatment of this blood-related cancer.
Novel drug targets imatinib-refractory leukemia: two studies suggest that nilotinib could provide an alternative for patients not benefiting from imatinib.(Hematology): ... An article from: Internal Medicine News
Orignal From: Novel drug targets imatinib-refractory leukemia: two studies suggest that nilotinib could provide an alternative for patients not benefiting from imatinib.(Hematology): ... An article from: Internal Medicine News
No comments:
Post a Comment